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collimator angle. The results are based on the value of GAI: 
when the value is lower than 95%, the error is detected. 
Introduced errors are smaller and smaller in order to 
characterize error detection limits of each method. 
For Portal Dosimetry, it is possible to detect errors of 
collimator angle up to 4° and errors of Monitor Units up to 
3%. For Delta4, it is possible to detect errors of collimator 
angle up to 2° and errors of Monitor Units up to 2 %. For 
Epiqa, it is possible to detect errors of collimator angle up to 
2° and errors of Monitor Units up to 3%. 
 
Conclusion: In spite of their differences, the three pre-
treatment verification methods are able to detect different 
sort of errors in dose distributions. The comparative study 
gives us concordant results. Therefore, these data suggest 
the possibility of using only one routinely and complete the 
analysis with one of the other in case of problems. 
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Purpose or Objective: In this study, we compared patient 
therapy planning evaluation system, applying MLC log file, 
with quality assurance system using the fluence map 
obtained from measurement, in order to assess usefulness of 
patient dose analysis system. 
 
Material and Methods: To map out IMRT treatment planning, 
we used 4 targets and organ contours (multiple targets, 
virtual prostate, virtual head & neck, C type), along with 
IMRT phantom as presented in AAPM TG-119 Report. The 
treatment planning was implemented via Eclipse treatment 
planning system using 7 radiation field at an interval of 50º 
from 0o for both multiple targets and virtual prostate on one 
hand and using 9 radiation fields at an interval of 40º from 0o 
for both virtual head & neck and C type on the other hand. 
For dose limitation conditions for PTV and critical structure, 
we adopted the objectives specified in TG 119 Report. In 
relation to dose evaluation, point dose was evaluated by 
using CC13 chamber. The gamma index was analyzed for 
allowable limit of 3%/3mm by using MobiusFx system, a dose 
analysis software using MLC log file, in tandem with 2D array 
detector and Compass software that evaluates dose based on 
fluence map. 
 
Results: Dose distribution was calculated using treatment 
planning and Mobius system for 4 targets and then compared 
through three-dimensional gamma index based on the setting 
criteria for allowable limit of 3%/3mm. The results showed 
the pass rate of 99.5% in multiple targets, 100.0% in prostate, 
99.5% in head & neck, and 99.8% in C type. Based on results 
of analysis of gamma index for dose distribution, which was 
performed on the basis of dose distribution calculated by 
MobiusFX system and MLC log file actually investigated, the 
pass rate was found to be 100.0% in multiple targets, 100.0% 
in prostate, 99.7% in head & neck, and 99.5% in C type. 
Meanwhile, gamma index was analyzed based on dose 
distribution under treatment planning for 4 targets and dose 
distribution measured through Compass system, and the 
results indicated that the pass rate was 99.9% in multiple 
targets, 99.6% in prostate, 99.2% in head & neck, and 98.8% 
in C type. In addition, the results of point dose evaluation, 
performed based on point dose under treatment planning 
using CC13 chamber and point dose actually measured, 
showed that difference in pass rate was 1.2% in multiple 
targets, 1.5% in prostate, 1.3% in head & neck, and 0.4% in C 
TYPE. 
 
Conclusion: This study may provide useful basis for ensuring 
quality assurance for each patient by using the MLC log 
analysis system during special treatments in clinical 
applications. 
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Purpose or Objective: The aim of this study was to assess 
the accuracy of the dosimertic algorithm based on the 
resolution of Boltzmann equation: “Acuros XB” (AXB) 
implemented in Eclipse (Varian) TPS. The methodology 
recommended by the IAEA-TECDOC-1583 was followed to 
evaluate AXB. AXB was also tested for clinical extra cranial 
stereotactic treatment cases. Moreover AXB with the two 
absorbed dose reporting options, dose-to-medium (Dm) and 
dose-to-water (Dw), was compared against the Analytical 
Anisotropic Algorithm (AAA). 
 
Material and Methods: The IAEA-TECDOC-1583 presents eight 
different fields configurations in heterogeneous media. All 
plans were created on a CIRS thorax phantom model 002LFC 
including different tissue equivalent inserts (water, bone and 
lung). Measurements were performed with a PinPoint 
ionization chamber (type 31016, PTW) on Novalis TrueBeam 
STx accelerator for 6MV and 10MV photons with and without 
flattening filter (6FF, 6FFF, 10FF, 10FFF). Furthermore, 
target absorbed dose difference between AXB (Dm and Dw) 
and AAA were compared using same monitor units for 17 
patients with non-small-cell lung cancer (NSCLC) or bone 
metastases cancer who underwent SBRT. 
 
Results: AXB Dm calculations showed an excellent agreement 
with measurements for the eight configurations of the IAEA-
TECDOC-1583. All the results fulfilled the agreement 
criterion given in the IAEA-TECDOC-1583. The biggest 
difference between measured and calculated absorbed dose 
with AXB (Dm and Dw) in lung was less than 0.6% for all 
photon energies. Unlike, in the lung region, AAA showed 
deviations that didn’t met the agreement criterion. Maximum 
deviations were 4.4%, 3.35%, 2.27% and 1.6% for respectively 
6FF, 10FF, 6FFF and 10FFF photon energies. Although the Dm 
and Dw was almost the same in most tissues for all the 
energies, comparing them in bony structure didn’t give 
similar results. When choosing Dw in the bone region some 
results didn’t fulfilled the agreement criterion, unlike Dm 
where excellent agreement were found between calculated 
and measured absorbed dose. For the planning target volume 
(PTV) in the NSCLC patients, AXB Dm and Dw calculations 
showed similar results while compared to the AAA 
calculations, where the average differences were less than 
2% for minimum, mean and maximum absorbed doses. For 
bone metastases cancer patients, comparing the PTV doses 
between AXB Dm and AXB Dw didn’t show similar results. The 
averaged deviations between AXB Dm and AAA were 1.7%, 
0.1% and 2.2% whereas deviations between AXB Dw and AAA 
were 0.1%, 4.2% and 0.7%, respectively for minimum, 
maximum and mean absorbed doses. 
 
Conclusion: The results of the IAEA-TECDOC-1583 and of 
clinical cases showed that the AXB algorithm is more 
accurate than AAA in the lung region for 6FF, 10FF, 6FFF and 
10FFF photons. As for bone metastasis the use of AXB Dm was 
recommended. 
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Purpose or Objective: The purpose of this study was to 
investigate the effect of the modeling of the treatment table 
top on the agreement between calculations and 
measurements on the Delta4 phantom (Scandidos). Also, the 
effect of the most suitable way to determine the daily 
correction factor was investigated. 
 
Material and Methods: Two of our linear accelerators are 
equipped with the standard Elekta iBeam evo carbon fiber 
table top. In our treatment planning system, Pinnacle v9.0 
(Philips), the table top is modeled as a slab with dimensions 
equal to the width and height of the table top and with a 
density of 0.25 g/cm³. 
We extended the axial dimensions of the artificial CT-image 
set of the Delta4 phantom provided by Scandidos from 25 x 
25 cm² to 50 x 50 cm² by a home-made program written in 
java. This allows us to place the table top model below the 
phantom at the real distance, ie 7 cm. 15 IMRT plans for 
breast cancer were recalculated twice, once on the CT-
images of the Delta4 phantom provided by Scandidos and a 
second time on the extended CT-images with the table top 
model included. All plans consist of 5 to 6 beams (87 in total) 
from which 1 to 2 beams go through the table (23 in total). 
The plans were exported to the Delta4 software and 
measured. In case no table top model was included in the 
calculations, a daily correction factor based on the average 
of 4 beams (gantry angles of 0°, 90°, 180° and 270°) was 
applied. When the table top model was included, a daily 
correction factor based on 1 beam (gantry angle of 0°) was 
applied. A gamma criterion of 3%/3mm was used. Statistical 
analysis was done by paired t-tests. A p-value < 0.05 was 
considered as statistically significant. 
 
Results: Without the use of daily correction factors, the 
mean pass rate for the overall treatment plans was 
respectively 90.7% (±6.9 SD) and 95.2% (±3.0 SD) without and 
with the table top model applied. This difference is 
significant with p = 0.01. In the first group 4 out of 15 pass 
rates were > 95%, whereas in the second group this is 9 out of 
15. With the use of the proper daily correction factors, this 
increases to respectively 98.6% (±1.2 SD) and 99.1% (±0.9 SD). 
This difference is also significant with p = 0.04. In both 
groups, all pass rates were > 95%. 
For individual beams going through the table top, the mean 
pass rate was respectively 90.8% (±9.9 SD) and 99.0% (±1.9 
SD) without and with the table top model applied and 
without the use of daily correction factors (p = 0.0001). In 
the first group 10 out of 23 pass rates were > 95%, whereas in 
the second group this is 22 out of 23. With the use of the 
proper daily correction factors, this increases to respectively 
99.0% (±1.6 SD) and 99.9% (±0.4 SD) (p = 0.01). In the first 
group 22 out of 23 pass rates were > 95% and in the second 
group all pass rates were > 95%. 
 
Conclusion: The table top modeling results in a better 
agreement between measurements and calculations, both for 
total plans and individual beams. This agreement improves 
when proper correction factors are applied. 
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Purpose or Objective: In-vivo dose verification is the last 
step of a quality assurance procedure to ensure that the dose 
delivered during treatment is in agreement with the 
prescribed one.This work reports the in-vivo dosimetry (IVD) 
results obtained by the SOFTDISO software (Best Medical 
Italy) during VMAT prostate cancer treatments. 
 
Material and Methods: SOFTDISO is based on a method 
developed by a cooperation between INFN and UCSC. It 
reconstructs in quasi-real time (a few seconds at the end of 
the fraction therapy) (i) the dose at the isocenter (Diso) in 
the patient from the transit signal acquired by the EPID and 
(ii) the comparison between EPID images obtained during the 
fractions of the therapy. In particular for each beam and 
fraction, the R ratios between the dose reconstructed at the 
isocenter point, Diso, in single-arc (179-181°) VMAT plans for 
prostate targets and the dose calculated by the TPS, 
Diso,TPS (generally about 2 Gy for fraction) obtained by 
Oncentra Masterplan, were computed. The acceptance 
criteria was: 0.95≤R≤1.05. Moreover the γ-analysis (2%-2mm) 
between portal images supplied useful index about the beam 
delivery reproducibility with the Pγ<1>95% and γ mean<0.4. 
15 patients with prostate cancer were treated with 6 MV 
photon beam delivered by an Elekta Synergy Agility (Elekta, 
Crawley). Our protocol required, for each patient, the IVD in 
the first three treatment sessions after a CBCT based set-up 
correction and the IVD test once weekly afterwards for the 
rest of the treatment course when the CBCT scan was not 
acquired. 
 
Results: The IVD procedure supplied 105 tests and the 
average R was equal to 1.003 ± 0.028 (1SD), in a range 
between 0.949 and 1.058. The global R value for each single 
patient was well-within the 5% tolerance level. The γ-analysis 
between EPID images supplied Pγ<1≥97% in 80% of the tests. 
20% of the tests supplied 93% ≤P γ<1<95% due to small setup 
variations as verified by the CBCT required at the end of the 
fraction therapy. 
 
Conclusion: The IVD results supported the protocol about the 
CBCT carried out in the first three treatment sessions of the 
VMAT prostate cancer treatment. The facility of the real time 
test supplied by SOFTDISO allows a CBCT scan requirement 
after the daily-fraction that supplies IVD off tolerance level. 
The authors intend to apply this procedure to estimate 
protocols about the use of the CBCT scans for other 
pathologies as the head-neck tumors where heavy dose 
variations due to morphological changes can occurs during 
the therapy. 
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Purpose or Objective: The study was aimed to check 
radiotherapy treatment accuracy and definition of action 
levels during implementation of in vivo dosimetry for 
treatment pelvic cancer patients as a part of quality 
assurance program. 
 
Material and Methods: Calibration and corrections factors for 
in vivo entrance dose measurements for n-type Isorad 
semiconductor diodes for photon energy of 15 MV were 
determined as per recommendations published by European 
Society for Radiotherapy and Oncology (ESTRO) Booklet No.5. 
The pelvic cancer patients for in vivo measurements have 
been divided into groups, according to radiation techique 
used, in order to investigate and detect the groups for which 
the uncertainty was larger or for which a systematic error 
occurred. Initial tolerance/action levels for all groups were 
set at level of 5 %. 
 
Results: In this study, entrance dose measurements were 
performed for total 185 treatment fields, of 95 pelvic cancer 
patients over one year period. In 6 (6%) out of 95 patients, in 
vivo measurements exceeded the tolerances. The mean value 
and the standard deviation for different groups were: Rectum 
and gynecology (four field box): 0.6%±3.07%(1SD), Prostate 
(five fields with wedges): +1.0%±2.22%(1SD). All pelvic 
measurements: +0.77%±2.79%(1SD). Larger standard deviation 
was shown for four field box cases because two large errors 
were noticed. After the corrections, in vivo dosimetry was 
repeated in both cases and the results were within the 
